Anti-Obesity Drugs - Global Strategic Business Report

  • ID: 834997
  • Report
  • Region: Global
  • 143 Pages
  • Global Industry Analysts, Inc
1 of 4

FEATURED COMPANIES

  • Eisai Co., Ltd. (Japan)
  • GlaxoSmithKline Plc. (UK)
  • VIVUS, Inc. (USA)
  • MORE
The report provides separate comprehensive analytics for the US, Canada, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2024. Market data and analytics are derived from primary and secondary research.

This report analyzes the worldwide markets for Anti-Obesity Drugs in US$ Million.

Company profiles are primarily based on public domain information including company URLs. The report profiles 25 companies including many key and niche players such as:
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Eisai Co., Ltd.
  • Novo Nordisk A/S
  • Rhythm Pharmaceuticals
  • VIVUS, Inc.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Eisai Co., Ltd. (Japan)
  • GlaxoSmithKline Plc. (UK)
  • VIVUS, Inc. (USA)
  • MORE

1. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

2. INDUSTRY OVERVIEW
Obesity and Overweight Statistics
Obesity - A Prelude
Anti-Obesity Drugs: A Market Characterized by High Unmet Needs
Currently Available Anti-Obesity Medications
Select Currently Available Short-term and Long-term Anti-Obesity Medication
Select Off-Label Drugs for Obesity
Saxenda Commands the AOM Market, Newer Drugs to Provide Impetus to Market Growth
Table 1: Prescription Uptake of Branded Anti-Obesity Drugs in the US (2016&2017): Estimated Number of Prescriptions (Thousands) for Belviq, Contrave, Qsymia and Saxenda (includes corresponding Graph/Chart)
Semaglutide: Highest Potential in the AOM Pipeline
Setbacks of Past Drugs
Positive Road Ahead for Belviq
Relaunch of Xenical
Relaunch of Contrave®
Reluctance among Patients, Physicians, and Payers Hurts Market Prospects
New Drug Development - High on the Agenda, Despite the Market Restraints
Anti-Obesity Drugs in Phase-III Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-II Clinical Trials: As of July 2018
Anti-Obesity Drugs in Phase-I Clinical Trials: As of July 2018
Diabetes Drug Companies Attempt to Foray into the Anti-Obesity Drugs Space
Competitive Landscape
Table 2: Worldwide Anti-Obesity Drugs Market by Leading Player (2017): Market Share Breakdown of Value Sales for Novo Nordisk, Orexigen, Eisai, Vivus, and Others (includes corresponding Graph/Chart)
Novo Nordisk - The Leading Player in the Market
Novo Nordisk’s Anti-Obesity Drugs in Pipeline
The United States - The Largest Obesity and Anti-Obesity Market
Europe - A Market with Vast Potential
Obesity Creeps Up in Developing Countries

3. GROWTH DRIVERS AND MARKET TRENDS
Alarming Rise in Global Obesity Levels - The Major Growth Factor
Classification of BMI
Table 3: Global Obesity Epidemic: Percentage of Overweight, Obese, and Severely Obese Adults for 2014 & 2025 (includes corresponding Graph/Chart)
Table 4: Severely Obese Population (in Thousands) Worldwide by Country: 2014 & 2025 (includes corresponding Graph/Chart)
Exponential Increase in Urban Population
Table 5: Urban Population Worldwide in Thousands: 1950-2050P (includes corresponding Graph/Chart)
Rising Incidence of Chronic Diseases Associated with Obesity Drive the Market Expansion
Table 6: Global Annual Medical Cost of CVD in US$ Billion: 2010, 2015, 2020, 2025, and 2030 (includes corresponding Graph/Chart)
Table 7: Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
Growing Middle Class Population to Drive the Market Growth
Table 8: Global Middle Class Population (in Millions) and as a Percentage of Total Population: 2005, 2015, 2025 & 2035 (includes corresponding Graph/Chart)
Table 9: Global Middle Class Spending (in US$ Trillion) by Geographic Region (2017E, 2025P & 2030P) (includes corresponding Graph/Chart)
Childhood Obesity - A Market with Unmet Needs
Table 10: Proportion of Overweight Children (Girls and Boys) in Total Population in Top 10 Countries with the Highest Overweight Children Population (includes corresponding Graph/Chart)
Table 11: US Proportion of Under Weight, Healthy Weight, Overweight and Obese Children in 10-13 Years Age Group (includes corresponding Graph/Chart)
Commercial Weight-Loss Companies Foray into the Market
Online Drug Stores Boost Sales
Barriers to Development of Effective Drugs
Regulatory Additions - A Barrier to Entry?
High Drug Development Costs - A Major Setback
Weight Loss Alternatives - A Market Dampener

4. SELECT RESEARCH INITIATIVES
Researchers Determine Molecular Structure of Neuropeptide Y1 Receptor
Researchers Develop new Antibody to Fight Obesity
Researchers Develop a New Drug that Reduce Fat Cells
NTU Scientists Develop a Microneedle Skin Patch
Researchers Explore Combination of Anti-Obesity Medicines for Enhanced Outcomes

5. OBESITY - AN INTRODUCTION
Understanding Fats
Obesity
Diagnosis of Obesity
BMI Calculation and Classification
Waist Circumference and BMI
Types of Obesity
Monogenic Obesity
Polygenic Obesity
Causes of Obesity
Unhealthy Eating Habits
Environmental and Genetic Factors
Sedentary Lifestyle
Alcohol Intake
Childhood Obesity
Psychological Factors
Pregnancy
Hormonal Disorders
Drugs
Aging
Risks Associated with Obesity
Obesity Treatment
Dietary Therapy
Exercise Therapy
Behavior Therapy
Pharmacotherapy
Weight Loss Surgery
Invasive Vis-à-vis Non-invasive Procedures
A Brief Review of Select Invasive Procedures
Bariatric Surgery
Laparoscopic Adjustable Gastric Banding (LAGB)
Vertical Banded Gastroplasty (VBG)
Roux-en-Y Gastric Bypass Procedure (RYGB)
Lap-Band Procedure
Gastric Band Procedure
Gastric Bypass Procedure
Doudenal Switch
Prescription Drugs Vis-à-vis Non-Prescription Drugs
Table 12: Obesity Treatment Options and Corresponding Success Rate

6. ANTI-OBESITY DRUGS - AN INSIGHT
Introduction
Mechanism of Action
Review of Available Prescription Anti-Obesity Drugs
Phentermine
Orlistat
Belviq (Lorcaserin)
Phentermine/Topiramate
Contrave®
Saxenda®

7. COMPETITIVE LANDSCAPE

7.1 Focus on Select Global Players
F. Hoffmann-La Roche Ltd. (Switzerland)
GlaxoSmithKline Plc. (UK)
Eisai Co., Ltd. (Japan)
Novo Nordisk A/S (Denmark)
Rhythm Pharmaceuticals (USA)
VIVUS, Inc. (USA)

7.2 Recent Industry Activity
Kallyope and Novo Nordisk Collaborate to Develop Novel Therapeutics for Diabetes and Obesity
Orexigen Completes the Sale of Contrave to Pernix
CohBar Presents Preclinical Data of CB4211 at the American Diabetes Association
CohBar Presents Preclinical Data of CB4209/CB4211 Program at the AASLD Liver Meeting
Novo Nordisk Launches Anti-obesity Drug in India
Orexigen Therapeutics in Partnership with Laboratorios Farmace´uticos Rovi, S.A. Launches Mysimba® in Spain
Eisai Acquires Global Rights for Developing and Marketing Belviq from Arena
Alvogen Partners with Vivus to Regulate, Sell, and Market Qsymia in the Republic of Korea
Boehringer Ingelheim Collaborate with Gubra to Develop Novel Peptide Compounds for Treating Obesity
Orexigen Therapeutics Agrees with Merck for Commercializing and Distributing Contrave in Latin America
VIVUS Enters into an Agreement with Alvogen to Market Qsymia( R) in the Republic of Korea
Orexigen Enters into Agreement with Cheplapharm to Distribute Mysimba™ in Austria, France, and Germany
Orexigen Expands Agreement with Biologix FZCO for Contrave® in the Middle East, with inclusion of Egypt
Novo Nordisk Plans to Enter Latin America for Selling Anti-Obesity Drugs
Rhythm Expands Setmelanotide's Phase 2 Clinical Trials to Treat Bardet-Biedl Syndrome Obesity
Rhythm Receives Expanded FDA Breakthrough Therapy Designation for Setmelanotide to Treat Rare Genetic Obesity Disorders
Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Navamedic ASA for Mysimba® in Five Nordic Countries
Orexigen Therapeutics Submits Contrave© to Health Canada for Marketing Approval
Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Bruno Farmaceutici S.p.A. for Mysimba® in Italy
Eisai Co., Ltd. Acquires All Rights of BELVIQ from Arena Pharmaceuticals, Inc. for Developing and Marketing
BELVIQ®, an anti-obesity agent, Receives Approval in Brazil
Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Biologix FZCO to Distribute Contrave® in the Middle East
Orexigen Therapeutics Enters into Agreement with Consilient Health Ltd. for Distributing and Commercializing Mysimba® in Ireland and the UK
Orexigen Therapeutics Agrees with Valeant to Distribute and Commercialize Contrave® in New Zealand and Australia
Orexigen Therapeutics Enters into Commercialization and Distributorship Agreement with Valeant Canada for Contrave®
Orexigen Therapeutics Enters into Agreement with Laboratorios Farmace´uticos Rovi, S.A. to Commercialize and Distribute Mysimba® in Spain
Orexigen Completes the Acquisition of All U.S. Rights to Contrave®
Eisai’s announces the Approval of Lorcaserin in Mexico
Orexigen Receives Approval for Contrave® in South Korea
Orexigen and Valeant Pharmaceuticals Team up to Commercialize and Distribute Mysimba® in Europe and Turkey
Eisai Announces the Availability of BELVIQ XR® in the United States

8. GLOBAL MARKET PERSPECTIVE
Table 13: World Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - US, Canada, Europe, Asia-Pacific, Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)
Table 14: World 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for US, Canada, Europe, Asia-Pacific, Latin America and Rest of World Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)

9. REGIONAL MARKET PERSPECTIVE

9.1 The United States
A. Market Analysis
Obesity Prevalence and Incidence Statistics
The US Anti-Obesity Drugs Market: A Review
Table 15: The US Anti-Obesity Drugs Market by Leading Player (2017): Market Share Breakdown of Value Sales for Novo Nordisk, Orexigen, Eisai, Vivus, and Others (includes corresponding Graph/Chart)
Childhood Obesity - Catching Them Young
Key Obesity Statistics: Opportunity Indicator
Table 16: Prevalence of Obesity in the US among Population aged 20 and Above, by Sex and Age (2015-2016) (includes corresponding Graph/Chart)
Table 17: Obesity Prevalence in the US among the population aged between 2 to 19 years, by Sex (2015-2016) (includes corresponding Graph/Chart)
Table 18: Trends in Obesity Prevalence among Population aged 20 and Over and Youth aged in between 2 and 19 Years in the US (2009-2016) (includes corresponding Graph/Chart)
Top Ranked States in the US based on Fatness, Obesity, and Overweight
Regulatory Environment
High Development Costs - A High Entry Barrier for Drug Makers
Obesity and Related Ailments: Burden on Societal and Economic Costs
B. Market Analytics
Table 19: The US Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.2 Canada
A. Market Analysis
Novo Nordisk’s Saxenda Weight-Loss Medication Awaits Approval in Canada (2018)
B. Market Analytics
Table 20: Canadian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.3 Europe
A. Market Analysis
Europe - An Opportune Market for Weight Management Drugs
B. Market Analytics
Table 21: European Recent Past, Current & Future Analysis for Anti-Obesity Drugs by Geographic Region/Country - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)
Table 22: European 10-Year Perspective for Anti-Obesity Drugs by Geographic Region/Country - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2018 and 2024 (includes corresponding Graph/Chart)

9.4.1 France
A. Market Analysis
Changing Lifestyle Alters Health Profile
B. Market Analytics
Table 23: French Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.4.2 Germany
A. Market Analysis
The Largest Anti-Obesity Market in Europe
B. Market Analytics
Table 24: German Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.4.3 Italy
Market Analysis
Table 25: Italian Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

8.4.4 The United Kingdom
A. Market Analysis
Anti-Obesity Drugs - the Need of the Hour as NHS Firefights Rising Peril of Obesity
B. Market Analytics
Table 26: The UK Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.4.5 Rest of Europe
A. Market Analysis
Review of Select Markets
Spain
Belgium
The Netherlands
Finland
Sweden
B. Market Analytics
Table 27: Rest of European Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.5 Asia-Pacific
A. Market Analysis
Brief Review of Select Countries
Australia
China
India
Korea
Use of Diet Pills Lack Proper Monitoring
New Zealand
B. Market Analytics
Table 28: Asia-Pacific Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.6 Latin America
A. Market Analysis
Mexico - A Review
B. Market Analytics
Table 29: Latin American Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

9.7 Rest of World
Market Analysis
Table 30: Rest of World Recent Past, Current & Future Analysis for Anti-Obesity Drugs Market Analyzed with Annual Sales Figures in US$ Million for Years 2015 through 2024 (includes corresponding Graph/Chart)

10. COMPANY PROFILES

Total Companies Profiled: 25 The United States (9)

  • Japan (2)
  • Europe (8)
    • Germany (1)
    • The United Kingdom (1)
    • Italy (1)
    • Rest of Europe (5)
  • Asia-Pacific (Excluding Japan) (6)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline Plc. (UK)
  • Eisai Co., Ltd. (Japan)
  • Novo Nordisk A/S (Denmark)
  • Rhythm Pharmaceuticals (USA)
  • VIVUS, Inc. (USA)
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll